Can I read Anti-inflammatories/mycophenolate: Congenital malformations following in-utero exposure: 7 case reports on EtoBox?

Anti-inflammatories/mycophenolate: Congenital malformations following in-utero exposure: 7 case reports is a Medicine article available to read on EtoBox.

What is Anti-inflammatories/mycophenolate: Congenital malformations following in-utero exposure: 7 case reports about?

Anti-inflammatories/mycophenolate Congenital malformations following in-utero exposure: 7 case reportsIn a retrospective comparative study conducted using the EudraVigilance database, 7 fetuses were described [sexes and exact ages not stated], who developed congenital malformations including neural tube defect, ventricular septal defect and patent foramen ovale, heart valve defect (tricuspid valve incompetence), spinal cord anomaly or corpus callosum agenesis following in-utero exposure to ixekizumab, belimumab, methotrexate, mycophenolate or vedolizumab.The mothers of fetuses had a history of immune-mediated inflammatory diseases. During the pregnancy, they received ixekizumab (one patient), belimumab and methotrexate (two patients), belimumab and mycophenolate (one patient) or vedolizumab (three patients). The fetuses developed congenital malformations secondary to in-utero exposure of the medications. The congenital malformations included neural tube defect secondary to ixekizumab (one patient), ventricular septal defect and patent foramen ovale secondary to belimumab and methotrexate (one patient), heart valve defect secondary to belimumab and mycophenolate (tricuspid valve inc

Who reads Anti-inflammatories/mycophenolate: Congenital malformations following in-utero exposure: 7 case reports?

Publisher

Springer Science and Business Media LLC

Published

2023

Language

EN

Field

Medicine (Health Sciences)